United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 7 minute read Pharma Industry News Vesper Bio reports 95% CSF progranulin boost in FTD-GRN trial—what’s next for VES001? Vesper Bio’s oral FTD therapy VES001 boosts CSF progranulin by 95%. Explore what this means for dementia prevention and future clinical milestones. bySrinathOctober 31, 2025